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195JACC Vol. 59, No. 2, 2012 Correspondence
January 10, 2012:192–5Finally, the lack of comparison of this new schema with one of
the most contemporary bleeding prediction tools for AF currently
available, HAS-BLED (4), is somewhat surprising, given the
inclusion of HAS-BLED in recent European and Canadian AF
guidelines. We note that many elements within the weighted (and,
hence, more complicated) ATRIA score are already covered by the
components within the more simple HAS-BLED score.
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Reply
We did not test the HAS-BLED score in our report (1) because
there was no internal validation in its original report (2). Risk
prediction models are prone to overconfidence; for 25 years, the
reporting standard has been internal validation through split-
sample testing, bootstrapping, or other techniques (3). Further, the
Euro Heart Survey, on which HAS-BLED was based, is prob-
lematic for follow-up studies of bleeds due to a relatively small
number of outcome events, missing follow-up in 30% of pa-
tients, and incomplete information on longitudinal warfarin use
(2). Incorporation of HAS-BLED into guidelines is not a substi-
tute for good methodologic practice.
Dr. Olesen and colleagues touch on important issues concerning
development of bleeding risk models (i.e., whether to include
nonanticoagulated patients, adjust for international normalized
ratio (INR) control, or restrict to new users). We continued the
tradition of most previous bleed models in focusing solely onwarfarin-treated patients. This mirrors the approach of stroke risk
schemes (e.g., CHADS2) that predict risk solely in patients off
nticoagulants and assume a fixed risk ratio in the alternative
herapy category. We did not include INR values because we
anted the model to address the anticoagulation decision before
tarting therapy and to allow our score to apply to novel antico-
gulants where INR testing is irrelevant. In ATRIA, the absolute
ncreased risk of bleeding among new users of warfarin was small,
nd we included both new and long-term warfarin users to
aximize power.
Dr. Olesen and colleagues are incorrect in asserting that we
xcluded patients with contraindications to warfarin therapy.
hysicians are, of course, less likely to prescribe warfarin to
atients at higher perceived bleeding risk, but this bias is present in
ll clinical studies of warfarin and should not necessarily affect our
odel’s accuracy. The counterintuitive “protective effects” of cer-
ain univariate findings were based on very small numbers of
vents; these variables dropped out in the multivariable phase. We
sed univariate hazard ratios1.5 as an objective quantitative basis
o select variables for the multivariable phase of model building.
his approach reduces false-positive findings. The variable age
75 years performed better than age 65 years in our model
uilding. Additionally, we tested previous stroke, and it did not
ass the bootstrapping threshold. Diagnosed hypertension did
eet criteria. We were unable to find support for the assertion that
ontrolled hypertension was not a bleeding risk factor in the paper
ited by Dr. Olesen and colleagues.
Predicting a heterogeneous outcome such as bleeding is a
aunting task. We based our model on the rich experience of a
arge community-based cohort and applied rigorous modeling
echniques. We welcome testing of our model in other relevant
atasets. Successful external validation plus incorporation into
ecision aids that thoughtfully balance bleed and stroke risk will
ictate the clinical usefulness of our ATRIA bleed risk score.
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